SLC6A3 and SLC6A3-related dopamine transporter deficiency syndrome: Figure 7G), thus providing direct evidence of the effectiveness of the rAAV approach in mouse model of DTDS. It is notable also that the general population of DAT-KO mice demonstrate lower weight compared to WT or heterozygous mice5. As another indication of normalized dopamine transmission following gene therapy, treated KO animals gained more weight compared to the KO control group (p = 0.003), as measured 48 days after surgery (Fig. 7H).